A vaccine advisory committee of the Centers for Disease Control and Prevention (CDC) has on Wednesday recommended routine use of Bavarian Nordic’s Jynneos vaccine against mpox in adults at risk of infection.

The Danish vaccine company announced this to the stock exchange on Wednesday evening.

According to an estimate from the CDC, the recommendation, if finally approved by the CDC and the US Department of Health and Human Services, will cover up to 2 million Americans, of which only 23% are currently fully vaccinated with two doses.

If the recommendations are approved, Bavarian Nordic expects to commercially launch Jynneos in the US in the first half of 2024.

”Our entry into the private market for mpox vaccines in the US represents an opportunity to improve access to Jynneos and to build a stable commercial business that complements our existing business with the US government to stockpile smallpox vaccines,” said Paul Chaplin, President and CEO of Bavarian Nordic, in the announcement.

(Translated using DeepL with additional editing by Mads Oddershede)